Published in Trends Cancer on September 01, 2015
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet (2016) 1.63
Targeting Protein-Protein Interactions in the HIF System. ChemMedChem (2016) 0.81
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov (2016) 0.80
XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice. PLoS One (2016) 0.75
Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. Elife (2017) 0.75
ETS-targeted therapy: can it substitute for MEK inhibitors? Clin Transl Med (2017) 0.75
A novel statistical approach for identification of the master regulator transcription factor. BMC Bioinformatics (2017) 0.75
Identification of breast cancer associated variants that modulate transcription factor binding. PLoS Genet (2017) 0.75
Super-Enhancer-Driven Transcriptional Dependencies in Cancer. Trends Cancer (2017) 0.75
Reduction-oxidation pathways involved in cancer development: a systematic review of literature reviews. Oncotarget (2017) 0.75
ETV4 and AP1 transcription factors form multivalent interactions with three sites on the MED25 activator-interacting domain. J Mol Biol (2017) 0.75
Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget (2017) 0.75
Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome Biol (2017) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 14.32
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2013) 12.36
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Lessons from the cancer genome. Cell (2013) 8.12
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
Identification of a primary target of thalidomide teratogenicity. Science (2010) 7.09
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 6.09
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol (2008) 5.90
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature (2014) 5.45
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 5.24
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 4.68
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science (2010) 4.52
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
Mechanisms of endocrine resistance in breast cancer. Annu Rev Med (2011) 4.32
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell (2013) 3.13
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell (2010) 3.05
Transcriptional regulation and its misregulation in disease. Cell (2013) 2.92
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 2.87
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell (2012) 2.59
Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol (2010) 2.58
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell (2010) 2.50
The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell (2014) 2.47
The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem (2001) 2.45
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature (2014) 2.33
DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science (2015) 2.29
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med (2013) 2.26
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature (2014) 2.11
Core-binding factors in hematopoiesis and immune function. Oncogene (2004) 2.04
Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev (2010) 1.92
Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A (1999) 1.88
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol (2015) 1.83
A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol (2010) 1.75
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol (2014) 1.70
The human glucocorticoid receptor: molecular basis of biologic function. Steroids (2009) 1.69
Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem (2003) 1.67
Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood (2014) 1.66
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med (2014) 1.64
A comprehensive view of nuclear receptor cancer cistromes. Cancer Res (2011) 1.64
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell (2010) 1.60
Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. Science (2015) 1.60
Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol (2010) 1.49
Myc and cell cycle control. Biochim Biophys Acta (2014) 1.44
p53 as a target for the treatment of cancer. Cancer Treat Rev (2014) 1.38
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Mol Cell (2015) 1.36
Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell (2013) 1.35
Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol (2010) 1.31
Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem (2004) 1.29
Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer (2006) 1.24
Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med (2014) 1.18
Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta (2012) 1.14
PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol (2013) 1.10
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell (2013) 1.09
The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst (2008) 1.04
A role for DOT1L in MLL-rearranged leukemias. Epigenomics (2011) 1.02
NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet (2015) 1.02
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med (2015) 0.99
An overview of current and emerging SERMs. J Steroid Biochem Mol Biol (2014) 0.98
Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol (2014) 0.95
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp Med (2013) 0.95
TNFα signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome. Mol Cell (2015) 0.94
Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med (2015) 0.93
Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis. Nat Struct Biol (2002) 0.92
All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J (Engl) (1987) 0.88
Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem (2014) 0.85
The evolution of prostate cancer therapy: targeting the androgen receptor. Front Oncol (2014) 0.83
The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies. J Intern Med (2014) 0.83
Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse. Lab Anim Res (2012) 0.82
Molecular mechanisms of hormone resistance of breast cancer. Bull Exp Biol Med (2013) 0.82
Utility of LHRH antagonists for advanced prostate cancer. Can J Urol (2014) 0.80
Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development. Front Cell Dev Biol (2014) 0.80
Treatment of early-stage HER2+ breast cancer-an evolving field. Ecancermedicalscience (2015) 0.79
Strategies for targeting the androgen receptor axis in prostate cancer. Drug Discov Today (2014) 0.78
Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5. Cell Rep (2014) 0.78